WEED Overview

Cannabis Stock Surge: Cannabis stocks rose on Thursday morning following news that President Trump is expected to sign an executive order to reschedule marijuana.

Rescheduling Marijuana: The proposed change would reclassify marijuana from a Schedule I drug, which includes substances like heroin, to a Schedule III drug, aligning it with some prescription medications.

Market Reaction: The cannabis sector had already seen a surge in stock prices the previous week due to preliminary reports about Trump's intentions regarding marijuana classification.

Implications of Rescheduling: Rescheduling marijuana could have significant implications for its legality, regulation, and market dynamics in the United States.

ETF Performance: The Roundhill Cannabis ETF (WEED) has reached a 52-week high, increasing by 226.5% from its low of $8.79 per share, attracting investor interest.

Market Drivers: Recent gains in cannabis stocks are attributed to President Trump's potential plans to ease federal marijuana regulations, which has boosted optimism among investors.

Future Outlook: The ETF shows a positive weighted alpha of 43.48, indicating the possibility of continued strong performance in the near term.

Investment Resources: Zacks Investment Research offers a free newsletter with actionable insights and top-performing ETFs, encouraging investors to stay informed.

Market Performance: Last week, the S&P 500 fell by 0.6%, while the Dow Jones rose by 1.1% and the Nasdaq dropped by 1.6%, primarily due to declines in tech stocks, including a 14% drop in Oracle's shares.

Federal Reserve Actions: The Fed implemented its final rate cut of the year, lowering the benchmark federal funds rate to 3.5%-3.75%, with projections indicating a more restrained outlook for 2026.

ETF Highlights: Notable ETF performances included significant gains in the cannabis sector, with the Roundhill Cannabis ETF up 51.2%, and strong performances in silver miners and the space economy, driven by rising demand and investor interest.

Emerging Trends: The Roundhill GLP-1 & Weight Loss ETF gained 6.3%, reflecting optimism in weight loss drugs as a major advancement in pharmaceuticals, while platinum prices surged due to anticipated market deficits.